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uring angiogenesis, endothelial cells initiate a tis-
sue-invasive program within an interstitial matrix
comprised largely of type I collagen. Extracellular
matrix–degradative enzymes, including the matrix metallo-
proteinases (MMPs) MMP-2 and MMP-9, are thought to
play key roles in angiogenesis by binding to docking sites
on the cell surface after activation by plasmin- and/or
membrane-type (MT) 1-MMP–dependent processes. To
identify proteinases critical to neovessel formation, an ex
vivo model of angiogenesis has been established wherein
D
 
tissue explants from gene-targeted mice are embedded
within a three-dimensional, type I collagen matrix. Unex-
pectedly, neither MMP-2, MMP-9, their cognate cell-surface
receptors (i.e., 
 
 
 
3
 
 integrin and CD44), nor plasminogen
are essential for collagenolytic activity, endothelial cell
invasion, or neovessel formation. Instead, the membrane-
anchored MMP, MT1-MMP, confers endothelial cells with
the ability to express invasive and tubulogenic activity in a
collagen-rich milieu, in vitro or in vivo, where it plays an
indispensable role in driving neovessel formation.
 
Introduction
 
Angiogenesis is a specialized form of branching morphogenesis
wherein endothelial cells detach themselves from the existing
vasculature, invade surrounding tissues, and reorganize into
patent tubules (Carmeliet and Jain, 2000; Pepper, 2001; Davis et
al., 2002; Lubarsky and Krasnow, 2003). In the postnatal state,
new blood vessels routinely traverse a dense connective tissue
matrix largely comprised of type I collagen, the major extra-
cellular protein found in mammals (Hay, 1991). Although the
triple-helical molecule is resistant to almost all forms of pro-
teolytic attack, endothelial cells engaged in the angiogenic
process are believed to negotiate this structural barrier by mobi-
lizing proteolytic cascades that converge on the matrix metallo-
proteinases (MMPs) progelatinase A (MMP-2) and progelatinase
B (MMP-9; Pepper, 2001; Davis et al., 2002; Heissig et al., 2003).
Like all members of the MMP family, MMP-2 and
MMP-9 are synthesized as latent enzymes (Egeblad and Werb,
2002, Seiki, 2002). However, coincident with the expression
of tissue-invasive or morphogenic processes, secreted MMP-2
and MMP-9 are activated. With specific regard to angiogenesis,
the serine proteinase plasmin has been proposed to act as
an activator of both MMP-2 and MMP-9, whereas multiple
members of the membrane-anchored family of MMPs (i.e.,
membrane-type [MT]1-, 2-, 3-, 4-, 5-, and 6-MMP) can process
the MMP-2 zymogen to its active form (Pepper, 2001; Davis et
al., 2002; Seiki, 2002). Surface localization of the activated
metalloproteinases may be critical for allowing cells to migrate
within dense connective tissues, as binding interactions between
MMP-2 and the 
 
 
 
v
 
 
 
3
 
 integrin, and between MMP-9 and the
cell surface proteoglycan CD44, have been associated with
invasive/angiogenic phenotypes (Brooks et al., 1996, 1998; Yu
and Stamenkovic, 1999; Silletti et al., 2001).
Despite the wealth of evidence supporting a role for
MMP-2, MMP-9, plasminogen, or MT1-MMP activity in angio-
genic events in vivo (Brooks et al., 1998; Itoh et al., 1998;
Bergers et al., 2000; Zhou et al., 2000; Heissig et al., 2003), the
means by which these proteinases exert their effects remain
largely undefined. Long thought to confine their activity to
degrading ECM components, increasing evidence suggests that
MMPs may modulate endothelial cell function indirectly by
activating latent cytokines, cleaving membrane-anchored tar-
gets, releasing matrix-bound growth factors, or generating
 
Correspondence to Stephen J. Weiss: sjweiss@umich.edu
Abbreviations used in this paper: 3-D, three-dimensional; CAM, chorioallantoic
membrane; HGF, hepatocyte growth factor; MMP, matrix metalloproteinase;
MT, membrane-type; TIMP, tissue inhibitor of metalloproteinase. 
JCB • VOLUME 167 • NUMBER 4 • 2004 758
 
bioactive neopeptides (Egeblad and Werb, 2002; Heissig et al.,
2003). Consequently, it remains unclear whether MMP-2,
MMP-9, their cognate receptors, or the upstream proteinases
responsible for their activation, directly support the crucial col-
lagen-remodeling events necessary to drive the morphogenic
programs associated with angiogenesis.
To identify the proteolytic systems required for neovessel
formation within a physiologically relevant interstitial matrix,
three-dimensional (3-D) gels of cross-linked type I collagen
were seeded with tissue explants or endothelial cells isolated
from mice harboring inactivating mutations in either the plas-
minogen, 
 
MMP-2
 
, 
 
MMP-9
 
, 
 
 
 
3
 
 
 
integrin
 
, 
 
CD44
 
, or 
 
MT1-MMP
 
genes. Unexpectedly, we demonstrate that neovessel formation
proceeds in unperturbed fashion in the absence of either plas-
minogen, MMP-2, MMP-9, the 
 
 
 
3
 
 integrin, or CD44. Instead,
the membrane-anchored collagenase MT1-MMP plays a re-
quired role in conferring endothelial cells with the ability to
both proteolytically remodel type I collagen and express a col-
lagen-invasive phenotype critical to the tubulogenic process.
 
Results
 
3-D neovessel formation engages a 
collagenolytic phenotype
 
To determine whether neovessel formation is linked to a col-
lagen remodeling process, mouse tissue explants were embed-
ded in a 3-D type I collagen gel, stimulated with a growth fac-
tor cocktail, and monitored for vessel outgrowth as well as
collagenolysis. After the egress of fibroblast-like cells during
the first two days of ex vivo culture (Fig. 1 A, a), capillary
sprouts emerge and coalesce to form an anastomosing network
of PECAM-1–positive vessels surrounded by pericyte-like
cells at day 7 (Fig. 1 A, b–f). Coincident with the expression of
the tubulogenic program, type I collagen degradation products
appear in the pericellular environment, as detected with anti-
bodies specific for either (1) the COOH-terminal neopeptide of
the three-quarter fragment of cleaved type I collagen or (2) de-
natured collagen products that have lost their triple-helical in-
tegrity (Fig. 1 B). Though the formation of capillary-like struc-
tures is associated with type I collagenolytic activity, the
degradative phenotype is coordinated with the neodeposition of
type IV collagen (Fig. 1 B) and laminin (not depicted) as ma-
turing neovessels initiate basement membrane synthesis (Nico-
sia and Madri, 1987).
Although multiple proteinases have been implicated in
the collagenolytic process (Davis et al., 2002; Heissig et al.,
2003; Shi et al., 2003), the formation of patent vessels is unaf-
fected by the broad-spectrum cysteine proteinase inhibitor
E-64d or the aspartyl proteinase inhibitor pepstatin A (not de-
picted). In contrast, cellular outgrowth, as well as tubulogene-
sis, is almost completely inhibited by the peptidomimetic MMP
inhibitor BB-94 (Fig. 1 C). As plasmin is thought to play a key
role in type I collagen turnover by virtue of its ability to partici-
pate in the processing of latent MMPs to catalytically active
forms (Pepper, 2001; Davis et al., 2002), neovessel outgrowth
was monitored in tissue explants isolated from plasminogen-
null mice that were cultured in plasminogen-null serum. Inter-
estingly, in the absence of plasminogen, an angiogenic response
indistinguishable from that displayed by wild-type controls is
observed, as determined on morphologic grounds (Fig. 1 C) or
by sprout density and length, respectively (6.0 
 
 
 
 2.6 sprouts
Figure 1. ECM remodeling during ex vivo neovessel formation. (A)
Neovessel formation from mouse aortic ring explants. After culturing for 2 d
in a 3-D type I collagen gel (2.2 mg/ml) in the presence of VEGF and HGF
(50 ng/ml each) and 20% FBS, vessel wall–associated cells initiate migra-
tion from matrix-embedded aortic rings (a; bar, 500  m). The asterisk indi-
cates the position of the aortic explant and the inset displays a scanning
electron micrograph of the type I collagen matrix that highlights the dense
packing of the surrounding fibrillar gel (bar, 5  m). Patent tubular struc-
tures form by day 5 (b) with PECAM-1–positive endothelial cells (c, green)
comprising the wall of the formed neovessels (c). Cell nuclei are stained
blue with DAPI (c; bar, 100  m). By phase-contrast microscopy, the newly
formed tubules (margins of a vessel are bordered by arrowheads) allow
the passive outflow of red blood cells that remain in the aortic rings after
isolation (d; bar, 50  m). Cross sections of sprouting neovessels display
tubular structures of varying diameters after a 7-d culture period (e; bar,
100  m), whereas transmission electron micrographs show that endothelial
cells line a patent lumen (f, asterisk) that is surrounded by pericyte-like
accessory cells (arrowheads; bar, 5  m). (B) Type I collagen degradation
products surrounding egressing neovessels, as detected with antibodies
directed against collagen neoepitopes generated after the proteolysis of
collagen into three-quarter and one-quarter fragments, are shown on the
left (green). Type I collagen denaturation products after proteolysis are
shown in the middle (red). Coincident with the generation of type I collagen
cleavage production, the endothelial cells deposit a matrix of type IV
collagen (right; green). Cell nuclei are stained blue with DAPI. (C) Neovessel
formation is blocked in the presence of 5  m BB-94 (neovessel length de-
creases from 1,079   20  m to 271   9  m, n   3), but proceeds in an
unaffected manner from aortic rings isolated from plg
 /  mice and cultured
in plg
 /  serum after a 7-d incubation period. 
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759
 
per field with a mean sprout length of 1,272 
 
 
 
 83 
 
 
 
m in wild-
type explants vs. 6.7 
 
 
 
 2.1 sprouts per field and a sprout length
of 1,359 
 
 
 
 22 
 
 
 
m for plasminogen-null explants; 
 
n
 
 
 
  
 
3).
 
Capillary morphogenesis proceeds 
independently of the MMP-2–
 
 
 
v
 
 
 
3
 
 or 
MMP-9–CD44 axes
 
The association of catalytically active MMP-2 with the 
 
 
 
v
 
 
 
3
 
 in-
tegrin has been reported to regulate the angiogenic response
(Brooks et al., 1996, 1998; Silletti et al., 2001), but the role that
this complex plays in directing invasive/tubulogenic programs
has not been defined. To determine the relative roles of MMP-2
and 
 
 
 
v
 
 
 
3
 
 in neovessel formation, we monitored vessel out-
growth and morphology in explants isolated from MMP-2–null
or 
 
 
 
v
 
 
 
3
 
-null mice. Although wild-type explants expressed both
MMP-2 and 
 
 
 
3
 
, as assessed by RT-PCR (not depicted), MMP-
2–null and wild-type littermate explants mounted an indistin-
guishable tubulogenic response, without significant differences
in mean capillary length or density (Figs. 2 A and 3 C). Fur-
thermore, morphogenesis proceeded in normal fashion, with a
ring of endothelial cells circumscribing a patent lumen (Fig. 2
A). Consistent with an MMP-2–independent tubulogenic pro-
gram, neither vessel outgrowth nor vessel morphology was in-
hibited in the absence of the 
 
 
 
3
 
 integrin (Figs. 2 B and 3 C).
In a fashion similar to that described for MMP-2, MMP-9
has also been linked to tissue-invasive events and angiogenesis,
in part, by associating with its cell surface–binding partner,
CD44 (Yu and Stamenkovic, 1999; Davis et al., 2002). How-
ever, capillary outgrowth and vessel morphogenesis were not
affected by the deletion of either MMP-9 or CD44 (Fig. 3).
Figure 2. The functional role of the MMP-2– 3 integrin axis in capillary
sprout formation. (A) Neovessel outgrowth from control littermate (left
column) and MMP-2–null (right column) mouse aortic rings suspended in
type I collagen gels and stimulated with VEGF–HGF in 5% wild-type or
MMP-2
 /  serum are shown, respectively, after a 7-d incubation period
(top). Cross sections of mature neovessels highlight the nearly identical
pattern of tubule formation assessed by either light microscopy (middle;
bar, 100  m) or transmission electron micrograph (TEM) analysis (bottom;
bar, 5  m). (B) Capillary sprouting from wild-type and  3 integrin–null
mouse aortic rings as assessed by phase-contrast microscopy at day 7 is
shown (top). Cross sections of the capillary sprouts from wild-type and  3-
null aortic rings display similar morphology (bottom).
Figure 3. Neovessel outgrowth from MMP-9– and CD44-null explants.
(A) Capillary outgrowth from control littermate (left) and MMP-9–null mouse
aortic rings (right) suspended in type I collagen gels and stimulated with
VEGF–HGF in 5% autologous serum do not exhibit obvious differences in
capillary number, length, or morphology, as assessed by phase-contrast mi-
croscopy (top) or in hematoxylin and eosin (H&E)–stained cross sections
(bottom) at day 7. (B) Capillary sprouting from wild-type and CD44-null
aortic explants prepared as in A, as assessed by phase-contrast microscopy
(top) or in H&E–stained cross sections (bottom) after 7 d. (C) Mean neovessel
length and density from aortic explants isolated from MMP-2
 / ,   3
integrin
 / , MMP-9
 / , and CD44
 /  mice and incubated in type I collagen
gels for 7 d with VEGF–HGF in 5% autologous serum are expressed as per-
cent control of the respective wild-type littermate (mean   1 SD, n   4). 
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The tubulogenic response mounted by tissue explants in-
volves multiple cell types (e.g., Nicosia and Madri, 1987) that
might conceivably mask or compensate for an endothelial cell–
specific defect in collagenolytic or invasive activity. Hence,
microvascular endothelial cells were isolated from MMP-2 and
MMP-9–null mice, and their ability to degrade a subjacent bed
of type I collagen fibrils or invade 3-D type I collagen gels was
assessed. As shown in Fig. 4 A, wild-type endothelial cells
stimulated with a VEGF–hepatocyte growth factor (HGF) mix-
ture proteolyzed a subjacent film of rhodamine-labeled col-
lagen in an area confined to the boundaries of the overlying cell
by a process sensitive to either tissue inhibitor of MP (TIMP) 2
or BB-94 (not depicted). Of note, subjacent collagenolytic ac-
tivity was not affected by targeting either 
 
MMP-2
 
 or 
 
MMP-9
 
(Fig. 4 A). Furthermore, consistent with the collagen-degrada-
tive phenotypes displayed by either population of null-endothe-
lial cells, 
 
MMP-2
 
 or 
 
MMP-9
 
 knockout cells retained the wild-
type capability to invade 3-D collagen gels (Fig. 4, B and C).
Invasion, like collagen degradation, was also blocked com-
pletely by both BB-94 and wild-type TIMP-2, but was not af-
fected by TIMP-1, a potent inhibitor of MMP-2 and MMP-9
(Hotary et al., 2003; Fig. 4 C). Although TIMP-2 can affect cell
function independently of its ability to block MMP activity
(Seo et al., 2003), endothelial cell invasion was not inhibited by
an Ala–TIMP-2 mutant devoid of anti-MMP activity (Fig. 4 C).
 
MT1-MMP regulates capillary sprouting, 
collagenolysis, and endothelial cell 
invasion in a type I collagen–specific 
fashion
 
Although neovessel formation, endothelial cell invasion, and col-
lagenolytic activity proceeded in an unperturbed manner in the
absence of either MMP-2 or MMP-9, recent studies indicate that
MT1-MMP can display collagenolytic activity directly (Ohuchi et
al., 1997; Atkinson et al., 2001). To determine whether MT1-
MMP controls endothelial cell–collagen interactions, MT1-
MMP–null aortic explants or microvascular endothelial cells were
recovered from the knockout mice in order to assess their ability
to (1) mount a tubulogenic program, (2) mediate subjacent col-
lagenolysis, and (3) express a collagen-invasive phenotype.
In contrast with wild-type explants, tissues isolated from
 
MT1-MMP
 
 
 
/
 
 
 
 mice are completely unable to generate neoves-
sels during a 7-d culture period (Fig. 5 A). Co-cultures of MT1-
MMP–null explants with wild-type aorta rings demonstrate
that soluble inhibitors of capillary formation are not released
from the knockout tissues and that wild-type tissues do not
generate soluble factors that are able to rescue the null pheno-
type (Fig. 5 A). Similar, if not identical, results are obtained
when explants of lung, myocardium, or skin are recovered
from MT1-MMP–null mice and tested ex vivo (unpublished
data). Furthermore, although neovessel formation by control
aortic explants resulted in the release of 6.2 
 
 
 
 1.1 
 
 
 
g hydroxy-
proline, 
 
MT1-MMP
 
 
 
/
 
 
 
 explants released only 1.2 
 
 
 
 0.6 
 
 
 
g hy-
droxyproline in the course of a 7-d culture period. In the pres-
ence of TIMP-2, collagenolysis by wild-type and 
 
MT1-MMP
 
 
 
/
 
 
 
explants was inhibited completely (0.4 
 
 
 
 0.3 
 
 
 
g and 0 
 
 
 
 0 
 
 
 
g
hydroxyproline released, respectively; 
 
n
 
 
 
  
 
3). Though MT1-
MMP has been posited to regulate cell function by activating
latent TGF
 
 
 
 or generating denatured collagen products that
mediate integrin signaling (Heissig et al., 2003), neither the ad-
dition of active TGF
 
 
 
 nor that of proteolyzed collagen affected
the 
 
MT1-MMP
 
 
 
/
 
 
 
 phenotype (unpublished data).
Consistent with the inability of 
 
MT1-MMP
 
 
 
/
 
 
 
 tissue ex-
plants to mount a tubulogenic program, isolated 
 
MT1-MMP
 
 
 
/ 
endothelial cells were unable to degrade subjacent collagen
Figure 4. A nonessential role of MMP-2 and MMP-9 in regulating the
collagenolytic and collagen-invasive activities of microvascular endothelial
cells. (A) Littermate control, MMP-2
 / , or MMP-9
 /  endothelial cells fo-
cally degrade a subjacent film ( 100  g) of fluorescently labeled type I
collagen after a 7-d culture period in the presence of VEGF–HGF and 5%
autologous wild-type or knockout sera. Areas of collagenolytic activity ex-
pressed by MMP-2
 / , MMP-2
 / , MMP-9
 / , and MMP-9
 /  correspond
precisely with sites subjacent to overlying endothelial cells as shown in
merged images of MMP-2–null, phalloidin-stained cells (top, right). Col-
lagenolytic activity by control littermate and null cells is completely blocked
by 3  g/ml TIMP-2 (bottom, right). Bar, 50  m. (B) Invasion of 3-D col-
lagen gels (2.2 mg/ml) by microvascular endothelial cells isolated from
wild-type (MMP-2
 / /C57BL6 and MMP-9
 / /129SvEv), MMP-2–null, or
MMP-9–null mice are shown after a 5-d incubation period with VEGF–
HGF in the presence of 5% autologous serum. Endothelial cell invasion
was insensitive to 3  g/ml TIMP-1, but inhibited completely by 3  g/ml
TIMP-2. Bar, 50  m. (C) The invasive activity of isolated wild-type,
MMP-2
 / , or MMP-9
 /  endothelial cells was quantified after a 5-d incu-
bation period in the absence or presence of BB-94, TIMP-1, TIMP-2, or
Ala-TIMP-2 mutant. Results are shown as the mean number of invading
cells per high powered field (hpf) in two experiments.MT1-MMP–DEPENDENT NEOVESSEL FORMATION • CHUN ET AL. 761
(Fig. 5 B) or invade 3-D collagen gels (Fig. 5 C). A requirement
for MT1-MMP during tissue-invasive activity was further con-
firmed by the inability of MT1-MMP–null endothelial cells to
penetrate an explant of collagen-rich human dermal tissue ex
vivo (Fig. 5 D). Despite the fact that MT1-MMP has been pos-
ited to regulate cell adhesion or migration by proteolyzing inte-
grins, cadherins, or surface enzymes (Gálvez et al., 2002; Seiki,
2002), MT1-MMP
 /  endothelial cells did not express defects
in their two-dimensional interactions with collagen, as the cells
migrated across type I collagen–coated surfaces at a rate indis-
tinguishable from that of controls (i.e., 29   1  m/24 h vs. 29  
1  m/24 h; n   3). Likewise, although MT1-MMP serves as
a necessary collagenolysin in endothelial cells, fibrin-invasive
and -degradative activity can be conferred by other members of
the membrane-anchored MMP family, including MT3-MMP
(Hotary et al., 2002). Given the ability of vessel explants as
well as isolated endothelial cells to express MT3-MMP (unpub-
lished data), morphogenesis and invasion through 3-D fibrin
Figure 5. A required role for MT1-MMP in neovessel formation, endothelial
cell invasion, and collagenolytic activity. (A) Aortic vessel explants isolated
from MT1-MMP–null mice display defective capillary sprouting (middle) com-
pared with wild-type tissue, after a 7-d culture period in type I collagen gels
in the presence of VEGF–HGF and 20% FBS (left) or 5% autologous serum
(not depicted). The co-culture of wild-type and MT1-MMP–null aortic rings
(left and right, respectively, of the right panel) does not affect the sprouting
behavior of wild-type or MT1-MMP–null explants. (B) Phalloidin-stained en-
dothelial cells (green) circumscribe zones of collagen degradation gener-
ated by wild-type, but not MT1-MMP
 / , cells cultured atop a type I collagen
film in the presence of VEGF–HGF in 20% FBS for 7 d. Bar, 10  m. Insets
show a low magnification image of multiple sites of collagenolysis relative to
the complete absence of degradation observed when MT1-MMP–null endo-
thelial cells are cultured atop fluorescently labeled collagen gels (bar, 50
 m). (C) In contrast with wild-type endothelial cells, MT1-MMP
 /  cells do
not invade 3-D type I collagen gels (2.2 mg/ml), as assessed by phase-con-
trast microscopy (bar, 50  m), in H&E–stained cross sections (bar, 50  m),
or by TEM analysis (bar, 5  m) after a 7-d culture period with VEGF–HGF in
the presence of 20% FBS. Arrowheads and asterisk indicate the positions of
invading MT1-MMP
 /  endothelial cells. (D) An acellular explant of type I/III
collagen–rich human dermis stained with Sirius red is infiltrated by GFP-
labeled control endothelial cells, but not by MT1-MMP–null endothelial cells.
The double-headed arrow marks the boundary of the explant tissue beneath
the monolayer of seeded endothelial cells. Bar, 100  m.
Figure 6. The fibrin-invasive activity of MT1-MMP–null explants and
endothelial cells. (A) Wild-type and MT1-MMP–null explants display com-
parable neovessel outgrowth and tubulogenic activity when embedded in
a 3-D gel of cross-linked fibrin (3.0 mg/ml) and cultured for 7 d with
VEGF–HGF in the presence of 5% mouse serum as assessed by phase-
contrast microscopy, in H&E–stained cross sections (representative vessels
marked with arrowheads), or by TEM analysis (middle and bottom, re-
spectively). (B) Isolated endothelial cells from wild-type or MT1-MMP–null
mice invade fibrin matrices (3.0 mg/ml) in comparable fashion in the
course of a 5-d incubation period in the presence of VEGF–HGF and 20%
FBS. Representative invading cells are marked with arrowheads. (C) Fibrin
invasion by isolated endothelial cells from wild-type and MT1-MMP–null
mice are comparable, and inhibited by 1  g/ml TIMP-2 but not 1  g/ml
TIMP-1 after a 5-d culture period under the conditions described above.
Results are shown as the number of invading cells per hpf (mean   1 SD
of 10 randomly chosen fields in two experiments).JCB • VOLUME 167 • NUMBER 4 • 2004 762
barriers was assessed in wild-type versus MT1-MMP
 /  tissues.
In contrast with their defect in collagen-invasive activity, MT1-
MMP–null explants mounted a tubulogenic phenotype in fibrin
gels that was comparable to that mounted by wild-type controls
(Fig. 6 A). Furthermore, both MT1-MMP
 /  and MT1-MMP
 / 
endothelial cells were able to invade fibrin gels via a TIMP-2-
inhibitable process (Fig. 6, B and C). Hence, we conclude that
(1) a requirement for MT1-MMP in tubulogenesis and invasion
is restricted to the type I collagen matrix; and (2) although
MT1-MMP has been reported to cleave a multiplicity of cell
surface–associated substrates (Seiki, 2002), invasion and tubu-
logenesis can proceed independently of MT1-MMP in a physi-
ologically relevant, but noncollagenous, matrix.
Structural requirements for MT1-MMP–
dependent endothelial cell collagenolysis 
and invasion in vitro and in vivo
To define the structural features that underlie the ability of
MT1-MMP to confer endothelial cells with collagen-degrada-
tive and -invasive activity, MT1-MMP–null endothelial cells
were transduced with wild-type MT1-MMP or MT1-MMP
variants harboring either an inactivating point mutation in the
catalytic domain or a deletion of the transmembrane domain
(Hotary et al., 2003). Although full-length MT1-MMP be-
stowed MT1-MMP
 /  endothelial cells with both collagenolytic
and invasive activity, catalytically inactive MT1-MMP did not
rescue the null phenotype (Fig. 7, A and B). Similarly, trans-
duction of MT1-MMP–null cells with a catalytically active, but
soluble, form of MT1-MMP failed to confer collagenolytic or
invasive activity, presumably because the recipient cell loses
its ability to focus proteolytic activity to the subjacent compart-
ment (Fig. 7, A and B).
Together, these results suggest that pericellular col-
lagenolysis, as well as invasive activity, minimally requires the
membrane display of a tethered collagenase. As such, MT1-
MMP activity could conceivably be compensated by other
members of the MT-MMP family that likewise express type
I collagen–degradative activity. Interestingly, recent studies
raise the possibility that MT2-MMP, though not normally ex-
pressed in mouse endothelial cells (unpublished data), can act
as an alternate membrane-anchored collagenolysin (Hotary et
al., 2000). Indeed, when MT1-MMP
 /  endothelial cells were
transduced with an MT2-MMP expression vector, subjacent
proteolysis was restored fully and in tandem with collagen-
invasive activity (Fig. 7, A and B). In contrast, a third member
Figure 7. Retroviral reconstitution of the collagenolytic and type I collagen–
invasive activity of MT1-MMP–null endothelial cells. (A) Although MT1-
MMP
 /  endothelial cells transduced with a control cDNA (top, left) were
unable to degrade a subjacent collagen film after a 7-d culture period
with VEGF–HGF in the presence of 5% mouse serum, retroviral reconstitu-
tion of active MT1-MMP restores the collagenolytic activity of MT1-MMP
 / 
endothelial cells (top, middle). Cells transduced with a catalytically inac-
tive MT1-MMPE/A mutant or a transmembrane-deleted, soluble form of
MT1-MMP (MT1-MMPsol) do not display collagen degradative activity.
Whereas the collagenolytic activity of MT1-MMP
 /  endothelial cells
could be rescued by expressing MT2-MMP, MT3-MMP–transduced cells
did not display a collagenolytic phenotype. Bar, 50  m. (B) Collagen-
invasive activity of MT1-MMP
 /  cells cultured atop a 3-D gel of type I col-
lagen (2.2 mg/ml) for 7 d in the presence of VEGF–HGF and 20% FBS is
rescued after transduction with MT1-MMP or MT2-MMP, but not EGFP,
MT1-MMPsol, MT1-MMPE/A, or MT3-MMP. The inset for MT1-MMP shows
the protein level of endogenous MT1-MMP in wild-type cells (lane 1), MT1-
MMP–null endothelial cells (lane 2), and MT1-MMP–transduced-null cells
(lane 3). The insets for MT2-MMP and MT3-MMP show the expression of
MT2-MMP and MT3-MMP, respectively, in wild-type cells (lane 1), and
MT1-MMP–null endothelial cells after retroviral transduction with MT1-
MMP, MT2-MMP, or MT3-MMP (lanes 2–4). (C) Immunofluorescent micro-
graphs of 11-d-old CAM cross sections depict a dense interstitial matrix
composed of types I and III collagen (top, left; bar, 50  m). MT1-MMP
 / 
or  MT1-MMP
 /  endothelial cells labeled with fluorescent microbeads
(green) invaded 144   55  m and 53   13  m, respectively, into the
CAM interstitium after a 3-d incubation (the CAM surface is marked by the
black arrowheads to the right; top, middle and right, and bottom; bar,
100  m). Retroviral gene transfer of GFP highlights the morphology of a
group of invading MT1-MMP
 /  cells (MT1
 / ; middle row, left and cen-
ter; bar, 20  m), which form tubular structures (left, arrows). The section of
the micrograph bounded by the dashed square is enlarged (middle) and
shows a group of elongated endothelial cells (arrowheads) forming a tubule
with the nuclei highlighted by Hoechst staining. Morphology of GFP-labeled
MT1-MMP
 /  endothelial cells (MT1
 / ) is shown (middle row, right). Af-
ter retroviral gene transfer of MT1-MMP or MT2-MMP into MT1-MMP
 / 
endothelial cells, invasion increased to 147   46  m and 123   34  m,
respectively. After retroviral gene transfer of MT1-MMP or MT2-MMP into
MT1-MMP
 /  endothelial cells, invasion increased to 147   46  m and
123   34  m, respectively (mean   1 SD, n = 3). The invasive activity of
MT3-MMP–transduced cells was not affected relative to the MT1-MMP
 / 
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of the MT-MMP family that displays little if any collagenolytic
activity, MT3-MMP (Hotary et al., 2000), was unable to rescue
the invasion-null phenotype (Fig. 7, A and B).
Finally, we sought to determine whether the ability of
MT1-MMP or MT2-MMP to confer invasive activity to MT1-
MMP
 /  endothelial cells could be extended from homogenous
3-D constructs of type I collagen in the in vitro setting to a
more complex interstitial barrier in vivo. Hence, wild-type
or MT1-MMP–null endothelial cells transduced with control,
MT1-MMP, MT2-MMP, or MT3-MMP retroviral expression
vectors were labeled with either fluorescent microbeads or
GFP and cultured atop the type I/III collagen–rich chick
chorioallantoic membrane (CAM; Fig. 7 C). Consistent with
the results obtained in vitro, wild-type, but not MT1-MMP–
null endothelial cells, were able to penetrate deeply into the
CAM interstitium. Furthermore, although GFP-labeled wild-
type endothelial cells adopted an elongated phenotype and dis-
played morphogenic properties by generating tubular structures
in the in vivo setting, MT1-MMP–null endothelial cells re-
mained spherical in shape and did not form tubules (Fig. 7 C).
Though the MT1-MMP
 /  phenotype was not rescued by over-
expressing MT3-MMP, tissue-invasive activity was restored
fully by expressing either MT1-MMP or MT2-MMP (Fig. 7
C). Thus, membrane-anchored collagenases uniquely confer
expressing cells with the proteolytic machinery necessary to
drive the invasive phenotype critical to morphogenic programs
in collagen-rich environments in vitro and in vivo.
Discussion
Angiogenesis, like the more generalized program of branching
morphogenesis, requires tissue-infiltrating cells to negotiate an
ECM rich in cross-linked type I collagen (Fisher et al., 1994;
Pepper, 2001; Seandel et al., 2001; Davis et al., 2002; Lubarsky
and Krasnow, 2003). Proteolytic remodeling of type I collagen
has been posited to play a necessary role in allowing numerous
cell types to generate a passageway through the matrix, migrate
across the newly exposed collagen substratum, and then engage
tubulogenic programs (Fisher et al., 1994; Tournier et al.,
1994; Lelongt et al., 1997; Haas et al., 1998; Miralles et al.,
1998; Zhu et al., 2000; Davis et al., 2001; Seandel et al., 2001;
Kheradmand et al., 2002). Although multiple proteolytic sys-
tems have been implicated in angiogenic events in vivo (Car-
meliet and Jain, 2000; Pepper, 2001; Davis et al., 2002), at-
tempts to identify enzymes critical to tissue remodeling per se
have been complicated by the more recent appreciation that the
substrate repertoire of MMPs extends to a diverse array of
growth factors, cytokines, chemokines, and cell adhesion mole-
cules (Egeblad and Werb, 2002).
Accumulating evidence supports an angiogenic scheme
in which endothelial cell–associated MMP-2 and MMP-9 drive
endothelial migration, invasion, or tubulogenesis (Haas et al.,
1998; Koivunen et al., 1999; Lyden et al., 1999; Xu et al.,
2001). Because MT1-MMP proteolyzes the MMP-2 zymogen
to its active form which, in turn, can activate MMP-9 (Seiki,
2002; Toth et al., 2003), we speculated initially that all three
MMPs would form a collaborative network to drive the angio-
genic response. Likewise, reports documenting the ability of
 v 3 and CD44 to localize MMP-2 and MMP-9, respectively,
to the migrating front of tissue-invasive cells are consistent
with a proteolytic model in which integrins and transmembrane
glycoproteins act as docking sites for the assembled protein-
ases (Brooks et al., 1996; Yu and Stamenkovic, 1999; Rolli et
al., 2003). Nonetheless, despite the appeal of such schemes,
neither MMP-2,  v 3, MMP-9, nor CD44 played a required
role in neovessel formation, endothelial cell collagen invasion,
or collagenolytic activity ex vivo. Likewise, although plasmin
has been linked to the angiogenic process (Carmeliet and Jain,
2000; Pepper, 2001), plasminogen-null explants displayed no
defects in our ex vivo model. In contrast, tissue explants recov-
ered from MT1-MMP
 /  mice were completely unable to
mount a tubulogenic response when suspended in collagen
gels. Furthermore, consistent with the proposition that col-
lagenolytic activity is required to support endothelial cell inva-
sion within a type I collagen–rich environment (Fisher et al.,
1994; Haas et al., 1998; Seandel et al., 2001; Davis et al.,
2002), MT1-MMP–null endothelial cells were unable to de-
grade subjacent collagen in a serum-containing milieu. Appar-
ently, MT1-MMP is the major, if not sole, collagenolysin oper-
ative in mouse endothelial cells that is capable of mediating the
pericellular dissolution of type I collagen under physiologic
conditions. Given that the MT1-MMP zymogen undergoes ef-
ficient processing to its active form via a proprotein conver-
tase–dependent process (Yana and Weiss, 2000), plasmin-
mediated processing of MT1-MMP does not play a required
role in this system. Although mouse endothelial cells express
soluble collagenases (e.g., MMP-13, MMP-2, and MMP-8) and
can use plasmin to activate these proteinases, these MMPs
were unable to mount a focal collagenolytic effect in the pres-
ence of serum antiproteinases (unpublished data). Hence, in the
absence of MT1-MMP activity, mouse endothelial cells fail to
degrade collagen or negotiate collagenous barriers. As human
endothelial cell tubulogenesis is also sensitive to TIMP-2, but
not TIMP-1 (Lafleur et al., 2002; Collen et al., 2003), we posit
that MT1-MMP and/or MT2-MMP play(s) a dominant role in
directing angiogenesis in humans as well.
Despite the correlation between collagenolytic and inva-
sive activity, MT1-MMP hydrolyzes not only type I collagen,
but also a variety of noncollagenous targets (Seiki, 2002; Ege-
blad and Werb, 2002). Consequently, we cannot eliminate the
possibility that MT1-MMP cleaves type I collagen in tandem
with other substrates in a fashion necessary to affect an invasive
and/or tubulogenic program. Our data do, however, rule out re-
cently proposed models wherein MT1-MMP drives invasion by
either processing the  v 3 integrin or cleaving CD44 (Deryu-
gina et al., 2000; Kajita et al., 2001; Mori et al., 2002). Further-
more, a more generalized defect in cell adhesion, migration, or
invasion that might be consistent with MT1-MMP–dependent
proteolysis of integrins, cadherins, growth factors, or surface
enzymes is not supported by our observations that MT1-MMP
 / 
cells migrate at normal rates across collagen-coated surfaces
and invade cross-linked fibrin barriers. Though recent studies
have suggested that MT1-MMP can regulate endothelial cell
migration (Gálvez et al., 2002), these conclusions are foundedJCB • VOLUME 167 • NUMBER 4 • 2004 764
on the use of neutralizing antibodies directed against MT1-
MMP. Because these antibodies do not recapitulate the MT1-
MMP
 /  phenotype and, in independent studies, affected the
activity of multiple membrane-anchored as well as secreted
MMPs (unpublished data), caution should be exercised in as-
suming their specificity or utility as MT1-MMP inhibitors.
The striking defects in collagenolytic and invasive activ-
ity, as well as in neovessel formation, displayed by MT1-
MMP
 /  tissues seem at odds with the fact that the null animals
develop normally (Holmbeck et al., 1999; Zhou et al., 2000). In
this regard, it is interesting to note that during embryogenesis,
as well as perinatally, the type I collagen content of most tis-
sues is low relative to the content in the postnatal state (Van
Exan and Hardy, 1984; Carver et al., 1993). As a possible con-
sequence, newborn null animals appear normal and only begin
to display serious skeletal and connective tissue abnormalities
after the first week of birth (Holmbeck et al., 1999; Zhou et al.,
2000). Hence, although the ECM composition of the develop-
ing animal may afford MT1-MMP
 /  animals a protected sta-
tus, we posit that the increased deposition of type I collagen
that arises as a consequence of the mechanical demands of
adult life initiates the onset of the pathologic states observed in
the knockout mice. Indeed, though null animals display an ap-
parently normal vasculature at birth, Zhou et al. (2000) have
reported that angiogenic responses in 15-d-old MT1-MMP
 / 
animals are abrogated in collagen-rich corneal tissues. None-
theless, even in collagen-replete tissues, our results suggest that
angiogenesis in fibrin-rich fields (e.g., wounds) may proceed
normally in MT1-MMP–null mice because MT3-MMP, though
largely devoid of collagenolytic activity, can function as an ef-
ficient fibrinolysin (Hotary et al., 2002).
Together, our observations appear to be at variance with
other in vitro or in vivo studies concluding that plasminogen,
MMP-2, or MMP-9 plays a required role in the angiogenic pro-
cess (Carmeliet and Jain, 2000; Brodsky et al., 2001; Pepper,
2001). However, it should be noted that defects in angiogenesis
have not been observed uniformly in either plasminogen
 / ,
MMP-2
 / , or MMP-9
 /  mice in response to wounding
(Romer et al., 1996; Itoh et al., 1998) or tumor growth (Bergers
et al., 2000; Hamano et al., 2003). Furthermore,  v 3
 /  mice
mount an exaggerated angiogenic response in a range of patho-
physiologic settings (Reynolds et al., 2002). In cases where
MMP-2 deficiency has been shown to affect neovasculariza-
tion, a partial reduction in the angiogenic response ( 30%) has
been most frequently described (Itoh et al., 1998; Berglin et al.,
2003; Guedez et al., 2003). In contrast, MMP-9–deficient mice
can, in some cases, display more significant defects in angio-
genesis in vivo, but this effect has been ascribed largely to the
ability of the metalloproteinase to release matrix-bound forms
of VEGF (Bergers et al., 2000). Indeed, vascular defects in
these animals are reversed by the exogenous application of
VEGF, despite the continued absence of MMP-9 (Engsig et al.,
2000; Heissig et al., 2003). Nonetheless, under defined circum-
stances, plasminogen, MMP-2, MMP-9,  v 3, or CD44 can
play an important role in modifying angiogenic events in vivo
(Carmeliet and Jain, 2000; Pepper, 2001; Davis et al., 2002;
Heissig et al., 2003; Oh et al., 2004), but based on our results,
these effects are more likely exerted in a fashion independent
of the matrix remodeling events associated strictly with inva-
sion or tubulogenesis within the 3-D interstitium. As the ex
vivo models used herein largely obviate a required role for en-
dogenous growth factors, chemokines, or immune cell popula-
tions, it may well develop that these latter players serve as pre-
ferred targets for plasminogen, MMP-2, or MMP-9 in vivo.
Similarly, the ex vivo model may circumvent a requirement for
basement membrane proteolysis, a key step in the initiation of
the angiogenic process, though it should be noted that angio-
genesis can proceed in a normal fashion in vivo even in the
combined absence of MMP-2 and MMP-9 (Baluk et al., 2004).
Clearly, a mounting number of observations describing normal,
or near normal, tubulogenic programs in MMP-2– or MMP-9–
null animals (Andrews et al., 2000; Bergers et al., 2000; Wise-
man et al., 2003) strongly suggest that tubulogenic programs—
including angiogenesis—can proceed in the absence of these
downstream MMPs. As such, the rules we have established for
generating patent neovessels in collagen-rich tissues raise the
possibility that MT1-MMP and perhaps MT2-MMP play domi-
nant roles in driving a variety of tubulogenic programs in the in
vivo, postnatal setting.
Materials and methods
Ex vivo angiogenesis assay
Mouse aortic ring assays were performed with minor modifications of pro-
tocols described previously (Nicosia and Madri, 1987; Hiraoka et al.,
1998). Mouse aortas were isolated from 4- to 5-wk-old male mice deficient
in either plasminogen, MMP-2, MMP-9, MT1-MMP,  3 integrin, or CD44,
or their respective littermate controls. Mice carrying null mutations for plas-
minogen (provided by T. Bugge, National Institutes of Health, Bethesda,
MD),  3 (provided by S. Teitelbaum [Washington University, St. Louis,
MO] and R. Hynes [Massachusetts Institute of Technology, Cambridge,
MA]), MMP-2 (provided by S. Itohara, RIKEN Brain Science Institute,
Saitama, Japan), or CD44 (provided by C. Doerschuk [Rainbow Babies
and Children’s Hospital, Case Western Reserve University, Cleveland,
OH] and T. Mak [Ontario Cancer Institute, University of Toronto, Toronto,
Ontario, Canada]) were backcrossed into the C57BL7 background for at
least 10 generations. MT1-MMP– and MMP-9–null mice were backcrossed
10 or more generations into the Black Swiss or 129SvEv backgrounds, re-
spectively (Romer et al., 1996; Itoh et al., 1998; Holmbeck et al., 1999;
Andrews et al., 2000; Reynolds et al., 2002; Wang et al., 2002). Iso-
lated aortas were sectioned (in 1-mm square fragments) and embedded in
2.2 mg/ml reconstituted type I collagen gels or 3.0 mg/ml cross-linked fi-
brin (Hotary et al., 2000, 2002) in 24-well plates and cultured in RPMI
1640 (GIBCO BRL) supplemented with either 20% FBS or 5% mouse sera
(prepared from wild-type littermate or null animals) in the presence of 100
ng/ml recombinant human VEGF-165, 50 ng/ml recombinant HGF (both
provided by Genentech, Inc., San Francisco, CA), and 100 pg/ml human
TGF-  (R&D Systems). In selected experiments, fragments were cultured in
the presence of 100  g/ml aprotinin (Sigma-Aldrich), 10  M E64d
(Sigma-Aldrich), 5  M pepstatin (Sigma-Aldrich), 5  M BB94 (British Bio-
technology), endotoxin-free recombinant human TIMP-1 or TIMP-2 (both
manufactured by Fujii), or Ala–TIMP-2 (provided by W. Stetler-Stevenson,
National Cancer Institute, Bethesda, MD).
After 7 d in culture, the collagen gel–embedded fragments were
fixed, the endothelial cells were immunostained with anti–mouse CD31
antibody (BD Biosciences) followed with Alexa Fluor 488 anti–rat IgG sec-
ondary antibody (Molecular Probes), and the nuclei were visualized with
DAPI (Vector Laboratories). Samples were mounted in Vector Shield (Vec-
tor Laboratories) and fluorescent or light images were captured by a mi-
croscope (DMLB; Leica; 5 /0.7 NA or 10 /0.7 NA objective lens)
equipped with a SPOT RT camera (Diagnostic Instruments). Neovessel
length was determined with SPOT software (Diagnostic Instruments) after
calibration, using an objective micrometer. For light and transmission elec-
tron microscopic studies, gels were fixed with 2% glutaraldehyde andMT1-MMP–DEPENDENT NEOVESSEL FORMATION • CHUN ET AL. 765
1.5% PFA in 0.1 M sodium cacodylate, pH 7.4 (Hotary et al., 2002).
Neovessel density was quantified by counting the number of tubules in six
or more cross sections taken 5 mm from the edge of the cultured aortic
rings in all four quadrants surrounding the embedded explants, after cap-
turing the images with a microscope (DMLB; Leica; 20 /0.7 NA objec-
tive lens) fitted with a SPOT RT camera. To visualize sites of collagen ma-
trix remodeling, we stained frozen sections with either the polyclonal
antibody against cleaved type I collagen (gift of A.R. Poole, McGill Uni-
versity, Montreal, Canada) or a monoclonal antibody directed against de-
natured type I collagen (Xu et al., 2001). Type IV collagen and laminin
were identified with polyclonal anti–type IV collagen (Oncogene Research
Products) and monoclonal antilaminin (Sigma-Aldrich) antibodies. Chicken
types I and III collagen were localized using anti–chicken types I and III
collagen antibodies, respectively (CHEMICON International). Alexa Fluor
488– or 594–conjugated anti–mouse or anti–rabbit antibodies (Molecular
Probes) were used as secondary antibodies. Sirius red staining was per-
formed as described by Canham et al. (1999). Type I collagen degrada-
tion during neovessel formation was quantified by hydroxyproline assay
(Creemers et al., 1997).
Endothelial cell invasive activity
Mouse dermal endothelial cells were isolated as described by Murphy et
al. (1998). The isolated cells were cultured on gelatin-coated dishes in
RPMI 1640 media with 5% mouse serum and supplemented with 100
 g/ml endothelial cell growth supplement (BD Biosciences). The endothe-
lial characteristics of the isolated cells were confirmed by von Willebrand
factor, CD31, and VE-cadherin staining (Murphy et al., 1998). DiI-Ac-LDL
uptake was  99%. To assess invasive activity, confluent monolayers of
microvascular endothelial cells were cultured atop type I collagen gels
(2.2 mg/ml), fibrin gels (3.0 mg/ml), or acellular explants of human der-
mis (Alloderm; Life Cell) in the upper compartment of Transwell dishes
(Costar) and exposed to a chemotactic gradient of VEGF (100 ng/ml)
and HGF (50 ng/ml).
Collagen film degradation assay
Type I collagen gel films ( 100  g) prepared on glass coverslips were la-
beled with tetramethylrhodamine isocyanate (Molecular Probes) for 45
min. Microvascular endothelial cells were cultured atop the collagen gels
in the presence of 100 ng/ml VEGF, 50 ng/ml HGF, and 5% autologous
serum. After 7 d, the samples were fixed, polymerized actin was visual-
ized with Alexa Fluor 488 phalloidin (Molecular Probes), and fluorescent
images were obtained by a laser scanning fluorescent microscope (model
LSM 510; Carl Zeiss MicroImaging, Inc.) equipped with acquisition soft-
ware (Version 3.2; Service Pck 2) using either 40  or 63  C-Apochro-
mat (1.2 NA) water immersion objective lenses at 25 C. Samples were
mounted in Vector Shield (Vector Laboratories).
Chick CAM assays
Endothelial cell invasion, before or after retroviral transduction, was deter-
mined in vivo using 11-d-old chick embryos wherein wild-type or MT1-
MMP–null endothelial cells were seeded atop the CAM for 3 d (Cameron
et al., 2000). To visualize endothelial cells, 10
5 cells were either labeled
with 0.05  m fluoresbrite carboxylate microspheres (Polysciences) or
transduced with a GFP retroviral vector. The mean depth of endothelial in-
vasion was determined by measuring the distance from the CAM surface
to the leading front of two or more invading endothelial cells in 10 or
more randomly selected fields, as assessed with a microscope (DMLB;
Leica)/SPOT RT camera system in at least two experiments.
Retroviral gene transfer
HA-tagged human MT1-MMP cDNA; soluble MT1-MMP (Met
1-Gly
535 that
lacks the COOH-terminal transmembrane and cytosolic domains of the
wild-type proteinase, and MT1-MMPsol), a catalytically inactive full-length
form of MT1-MMP that harbors an E
240 to A substitution in its catalytic do-
main (MT1-MMPE/A); or mouse cDNA clones for MT2-MMP and MT3-
MMP (provided by M. Seiki, University of Tokyo, Tokyo, Japan) were sub-
cloned into pRET2 retroviral vector derived from the Moloney murine leu-
kemia virus–based MFG backbone (Morita et al., 2001). The control pRET
vector carried an EGFP cDNA. Subconfluent monolayers of the isolated
endothelial cells were cultured in the retroviral supernatant for 12 h in the
presence of 100  g/ml endothelial cell growth supplement and collagen
invasion and degradation assays were performed 24 h later. The expres-
sion of MT1-MMP, MT2-MMP, and MT3-MMP was confirmed by Western
blot analysis using polyclonal anti–MT1-MMP antibody (Yana and Weiss,
2000) and monoclonal anti–mouse MT2-MMP and MT3-MMP antibodies
(Calbiochem), respectively.
RT-PCR analysis
Endothelial cells were cultured atop type I collagen gels in the presence of
100 ng/ml VEGF and 50 ng/ml HGF in 10% serum, and total RNA was
isolated using TRIzol reagent (GIBCO BRL). RT-PCR was performed using
One-Step RT-PCR System reagent (Life Technologies). The identities of the
PCR products were confirmed by sequence analysis.
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